Pharma associations take action over national European off-label authorisation laws

Published: 15-Sep-2015
Regulatory

They could be a disincentive to pharma companies developing drugs for rare diseases


National laws within the European Union (EU) that promote the off-label use of medicines are illegal under EU law and could disincentivise pharmaceutical companies from developing certain medicines, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has claimed.

Faraz Kermani, EFPIA External Affairs Communications Manager warned that medicines used for off-label applications have not gone through the same quality control as approved drugs, such as rigorous testing and reviews by the European Medicines Agency (EMA) and the European Commission.

'So you’ve done all that work, put in all that investment in order to come out with an end product that you know has the quality, efficacy, and ultimately the safety to be used in that particular condition. Then someone comes along and says… ‘this drug seems to be doing the same thing’ – that’s not good enough,' he added.

Medicines used for off-label applications have not gone through the same quality control as approved drugs

The EFPIA, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and the European Association for Bioindustries (EuropaBio) filed a complaint on 31 August against a French law allowing the country’s medicines regulator (ANSM – Agence Nationale de Sécurité du Médicament et des Produits de Santé) to issue a temporary authorisation for a medicine to be used for an unapproved purpose for economic reasons, even if there is an authorised alternative treatment. The ANSM did not respond to requests for comment.

This follows another complaint filed on 28 January by the organisations to the Commission against a similar Italian law.

Kermani added that off-label use could jeopardise patient safety, disincentivise companies particularly from developing orphan drugs (for rare medical conditions), and could lead to confusion over which party is held legally responsible for the off-label use.

He argued that the new French and Italian laws were particularly aimed at allowing the use of Avastin – a cancer drug – for macular degeneration (wet AMD), although the more expensive Lucentis is approved for that use.

The EFPIA and its partners are awaiting a response from the European Commission.

  • Companies:
  • EFPIA
  • EuropaBio
See more

You may also like

Media

Life Science Industry Coalition position paper released

Read more
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU

Trending Articles

  1. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  4. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  5. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Media

Life Science Industry Coalition position paper released

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Laying a new path for orphan drugs

Important changes in the way that the EU deals with orphan medicines could be signalled later this year when the European Commission publishes a revised version of its 2003 Communication (policy paper) on the topic
Regulatory

EU pharma associations seek orphan drug reform

One key issue is the need to demonstrate that an orphan medicine has a significant benefit over existing treatments
Regulatory

EFPIA says dedicated facilities not needed if EMA cross-contamination guidance works

Comments on a draft European Medicines Agency (EMA) guideline on setting health-based exposure limits for assessing the risk of manufacturing different medicinal products in shared facilities
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

EU celebrates 50 years of pharmaceutical legislation

<i>Manufacturing Chemist</i> asked public health organisations, industry and the academic community for their views on half a century of EU pharmaceutical legislation. The responses suggest that some organisations believe that it is far from perfect
Regulatory

European industry associations seek international co-ordination on cocrystal regulation

Salts and cocrystals can equally be accepted as drug substances
Regulatory

EFPIA calls for more flexibility in EU GMP advice on qualification and validation

There could be more need in future to concurrently 'validate' products earlier in the lifecycle
Subscribe now